Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 2
2006 3
2007 6
2008 4
2009 4
2010 1
2011 2
2013 2
2014 4
2015 2
2016 2
2017 1
2018 2
2019 3
2020 1
2021 3
2022 3
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean eun young song[Author] (193 results)?
Mitophagy deficiency increases NLRP3 to induce brown fat dysfunction in mice.
Ko MS, Yun JY, Baek IJ, Jang JE, Hwang JJ, Lee SE, Heo SH, Bader DA, Lee CH, Han J, Moon JS, Lee JM, Hong EG, Lee IK, Kim SW, Park JY, Hartig SM, Kang UJ, Moore DD, Koh EH, Lee KU. Ko MS, et al. Among authors: hong eg. Autophagy. 2021 May;17(5):1205-1221. doi: 10.1080/15548627.2020.1753002. Epub 2020 May 13. Autophagy. 2021. PMID: 32400277 Free PMC article.
A patient-centric approach to optimise insulin therapy in Asia.
Goh SY, Ang E, Bajpai S, Deerochanawong C, Hong EG, Hussein Z, Joshi S, Kamaruddin NA, Kho S, Kong AP, Pan CY, Perfetti R, Vichayanrat A, Vlajnic A, Chan JC. Goh SY, et al. Among authors: hong eg. J Diabetes Complications. 2016 Aug;30(6):973-80. doi: 10.1016/j.jdiacomp.2016.05.019. Epub 2016 May 24. J Diabetes Complications. 2016. PMID: 27288201 No abstract available.
Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION).
Lee BW, Min K, Hong EG, Ku BJ, Kang JG, Chon S, Lee WY, Park MK, Kim JH, Kim SY, Song K, Yoo SJ. Lee BW, et al. Among authors: hong eg. Endocrinol Metab (Seoul). 2023 Jun;38(3):328-337. doi: 10.3803/EnM.2023.1688. Epub 2023 Jun 28. Endocrinol Metab (Seoul). 2023. PMID: 37408283 Free PMC article. Clinical Trial.
Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension.
Moon JS, Park IR, Kim HJ, Chung CH, Won KC, Han KA, Park CY, Won JC, Kim DJ, Koh GP, Kim ES, Yu JM, Hong EG, Lee CB, Yoon KH. Moon JS, et al. Among authors: hong eg. Diabetes Metab J. 2023 Nov;47(6):808-817. doi: 10.4093/dmj.2022.0387. Epub 2023 Sep 26. Diabetes Metab J. 2023. PMID: 37750183 Free PMC article. Clinical Trial.
Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial.
Han KA, Kim YH, Kim DM, Lee BW, Chon S, Sohn TS, Jeong IK, Hong EG, Son JW, Nah JJ, Song HR, Cho SI, Cho SA, Yoon KH. Han KA, et al. Among authors: hong eg. Diabetes Metab J. 2023 Nov;47(6):796-807. doi: 10.4093/dmj.2022.0315. Epub 2023 Feb 9. Diabetes Metab J. 2023. PMID: 36756676 Free PMC article. Clinical Trial.
A 52-week efficacy and safety study of enavogliflozin versus dapagliflozin as an add-on to metformin in patients with type 2 diabetes mellitus: ENHANCE-M extension study.
Sohn TS, Han KA, Kim Y, Lee BW, Chon S, Jeong IK, Hong EG, Son JW, Na J, Cho JM, In Cho S, Huh W, Yoon KH. Sohn TS, et al. Among authors: hong eg. Diabetes Obes Metab. 2024 Jun;26(6):2248-2256. doi: 10.1111/dom.15537. Epub 2024 Mar 8. Diabetes Obes Metab. 2024. PMID: 38456558 Clinical Trial.
48 results